{"title": "Modelling the epidemiological trend and behavior of COVID-19 in Italy", "doi": "10.1101/2020.03.19.20038968", "citation_id": "2020.03.19.20038968v1", "date": "2020-03-23", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.19.20038968", "abstract": "<p>As of March 16, 2020, over 185,000 across the world, Italy became the red hotspot for the COVID-19 pandemic after China. With over 35,000 cases and 2900 deaths reported in the month of March in Italy, it is necessary to stimulate epidemic trend to understand the behavior of COVID-19 in Italy. By S.E.I.R. simulation, we estimated the most representative epidemic parameters occurred from March 1 to 14, 2020, thus being able to evaluate the consistency of the containment rules and identify possible Sars-Cov-2 local mutations. Our estimations are based on some assumptions and limitations exited.</p>", "twitter_description": "As of March 16, 2020, over 185,000 across the world, Italy became the red hotspot for the COVID-19 pandemic after China. With over 35,000 cases and 2900 deaths reported in the month of March in Italy, it is necessary to stimulate epidemic trend to understand the behavior of COVID-19 in Italy. By S.E.I.R. simulation, we estimated the most representative epidemic parameters occurred from March 1 to 14, 2020, thus being able to evaluate the consistency of the containment rules and identify possible Sars-Cov-2 local mutations. Our estimations are based on some assumptions and limitations exited.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNo external funding was received.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038968v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038968v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038968v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/23/2020.03.19.20038968.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), CC BY-NC 4.0, as described at http://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.19.20038968v1", "access_rights": "restricted", "authors": ["Alessandro Rovetta", "Akshaya Srikanth Bhagavathula"]}